Dofetilide

Antiarrhythmic — CARDIOVASCULAR SYSTEM

Key facts

Dofetilide is an ofp drug in the Antiarrhythmic class catalogued in DrugCentral. It was first approved by the FDA in 1999. DrugCentral lists 3 molecular targets, including KCNH2, KCNH1 and KCNK2. Recorded indications include Atrial fibrillation, Cardioversion of Atrial Fibrillation and Cardioversion of Atrial Flutter.

• Approval status: ofp (first approved 1999 by the FDA).
• Drug class: Antiarrhythmic.
• Molecular targets: KCNH2, KCNH1 and KCNK2 (3 listed in DrugCentral).
• Indications: Atrial fibrillation, Cardioversion of Atrial Fibrillation and Cardioversion of Atrial Flutter.
• ATC code: C01BD04 (Antiarrhythmics, class III).
• Molecular formula: C19H27N3O5S2; molecular weight 441.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Atrial fibrillation
• Cardioversion of Atrial Fibrillation
• Cardioversion of Atrial Flutter

Contraindications (12)

• Acute nephropathy
• Anorexia nervosa
• Congenital long QT syndrome
• Disease of liver
• Hyperhidrosis
• Hypokalemia
• Hypomagnesemia
• Kidney disease
• Prolonged QT interval
• Severe diarrhea
• Torsades de pointes
• Vomiting

Mechanism & targets

• Established pharmacologic class: Antiarrhythmic

Molecular targets (3)

Target	Gene	Action	Activity
Potassium voltage-gated channel subfamily H member 2	KCNH2	blocker	Ki 8.19
Potassium voltage-gated channel subfamily H member 1	KCNH1	blocker	IC50 7.50
Potassium channel subfamily K member 2	KCNK2	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1999-10-01	FDA	—	PFIZER

ATC classification

ATC code	Therapeutic hierarchy
C01BD04	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class III

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Electrocardiogram QT prolonged	962.9
Torsade de pointes	504.7
Ventricular tachycardia	313.3
Atrial fibrillation	271.9
Death	244.8
Arrhythmia	155.4
Palpitations	116.7
Ventricular fibrillation	112.1
Cardiac arrest	88.2
Therapy cessation	86.6
Atrial flutter	83.3
Cardioversion	80.7

Chemical structure

• Molecular formula: C₁₉H₂₇N₃O₅S₂
• Molecular weight: 441.56 g/mol
• CAS number: 115256-11-6
• InChIKey: IXTMWRCNAAVVAI-UHFFFAOYSA-N
• PubChem CID: 71329

CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dofetilide used for?

DrugCentral lists the following indications for Dofetilide: Atrial fibrillation, Cardioversion of Atrial Fibrillation and Cardioversion of Atrial Flutter.

How does Dofetilide work?

Its molecular targets in DrugCentral include KCNH2 (blocker), KCNH1 (blocker) and KCNK2.

When was Dofetilide first approved?

Dofetilide was first approved by the FDA in 1999.

What drug class does Dofetilide belong to?

Dofetilide is in the Antiarrhythmic class.

What is the chemical formula of Dofetilide?

Dofetilide has the molecular formula C19H27N3O5S2 and a molecular weight of 441.56 g/mol.

Sources

• DrugCentral drug card 942 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL473 — compound record and bioactivity
• PubChem CID 71329 — chemical identifiers
• DrugBank DB00204 — drug record
• FDA UNII R4Z9X1N2ND — substance identity
• DailyMed: FDA labels for Dofetilide — current prescribing information (label search)
• UniProt Q12809 (KCNH2) — target protein
• UniProt O95259 (KCNH1) — target protein
• UniProt O95069 (KCNK2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.